| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Repligen Corporation$134.38
+2.84 (+2.16%)
C 44Pipeline Score Tools & Services · Commercial
Market Cap
6.49 B
EPS
0.91
P/E Ratio
126.66 $
Value Trade
80.44 M
SEC Financials
Q1 2026Dilution Risk
Revenue
194.25 M
R&D Expenses
14.46 M
Operating CF
28.30 M
Total Assets
2.93 B
Total Liabilities
825.31 M
Equity
2.11 B
D/E Ratio
12,345
10.15 %
Week
-14.19 %
1 Month
-14.93 %
3 Month
-26.48 %
6 Month
-36.81 %
5 Year
922.76 %
All Time
Cash Data
Cash Position
784.53 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
406.00 K
52 Week Range
100.99 - 175.77
% held by Insiders
5.41 %
% held by Institutions
117.77 %
Enterprise Value
6.39 B
Total Shares
56.38 M
Short %
11.17 %
Float Shares
55.93 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C44
Pipeline Score $442M
Pipeline ValueValuation Signal
5
Drugs Scored0.2x
rNPV / MCap Top 65%
Small Cap (rank 318 of 905)
Percentile RankRepligen Corporation carries a moderate pipeline score (44/100), with $1.4B risk-adjusted pipeline value, led by RG1068 in Autism (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RG1068 Small molecule | Pancreatitis | Phase 3 | NCT00660335 | 50% | $464M | COMPLETED | 258 | - | - | Oct 1, 2009 | - | Dec 3, 2009 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RGEN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
RGEN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RGEN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RGEN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RGEN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
RGEN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RGENRepligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
Repligen Corporation will present at the William Blair 46th Annual Growth Stock Conference on June 3rd. CEO Olivier Loeillot will provide a company overview during the event. A live webcast will be available for those unable to attend in person. Repligen focuses on bioprocessing technologies for biopharmaceutical manufacturing.
Read more →RGENRepligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
Repligen Corporation has published its 2025 Corporate Sustainability Report, highlighting its commitment to sustainability across six key impact areas. The report includes disclosures aligned with the UN Sustainable Development Goals and various reporting frameworks. Key achievements include maintaining renewable energy in operations and adopting new sustainability policies. The company emphasizes transparency and continuous improvement in its sustainability efforts.
Read more →RGENRepligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference
Repligen Corporation will present at the Bank of America Securities 2026 Global Healthcare Conference from May 12-14 in Las Vegas. CFO Jason Garland will lead an analyst discussion on May 12 at 10:00am PT. A live webcast of the presentation will be available on Repligen's Investor Relations website.
Read more →RGENRepligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen Corporation reported a strong first quarter for 2026, with revenues reaching $194 million, marking a 15% increase year-over-year. The company also saw significant growth in earnings per share, with a 50% rise in GAAP EPS. Repligen reiterated its guidance for organic revenue growth and adjusted EPS for the full year, reflecting confidence in its strategic initiatives and market position.
Read more →RGENRepligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network
Repligen Corporation has inaugurated its new Training & Innovation Center in Breda, Netherlands, aimed at enhancing customer support through hands-on training and product demonstrations. This facility is the third of its kind globally, joining locations in Waltham and Tokyo. The opening reflects Repligen's commitment to investing in customer proximity and expanding its bioprocessing technology offerings.
Read more →RGENRepligen Corporation to Present at Upcoming March Conferences
Repligen Corporation will participate in three investor conferences in March 2026, including the Leerink Global Healthcare Conference and the Barclays Annual Global Healthcare Conference. CFO Jason Garland will lead discussions at both events, while CEO Olivier Loeillot will speak at the KeyBanc Virtual Healthcare Forum. Webcasts of the presentations will be available for investors.
Read more →RGENRepligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Repligen Corporation reported strong financial results for Q4 2025, achieving 14% organic growth, primarily driven by its Analytics and Proteins segments. The company exceeded its revenue guidance for the year and anticipates continued growth in 2026, despite facing a potential headwind from gene therapy. Repligen's CEO expressed optimism about their product portfolio and operational strategy moving forward.
Read more →RGENRepligen to Report Fourth Quarter and Full Year 2025 Financial Results
Repligen Corporation will announce its fourth quarter and full year 2025 financial results on February 24, 2026. A press release will precede the market opening, followed by a conference call at 8:30 a.m. ET to discuss the results. The call will be accessible to both domestic and international callers, with a webcast available on the company's website.
Read more →RGENRepligen Corporation to Present at Evercore Healthcare Conference
Repligen Corporation will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, in Coral Gables, Florida. CFO Jason Garland is scheduled for an analyst-led discussion on December 3 at 1:20 p.m. ET. A live webcast will be available on the company's Investor Relations website, with a replay option following the event.
Read more →RGENRepligen Corporation to Present at Upcoming November Conferences
Repligen Corporation announced its participation in five upcoming investor conferences. The company focuses on bioprocessing technology and will provide live webcasts of the presentations. This initiative reflects Repligen's commitment to engaging with investors and showcasing its innovative solutions in the biopharmaceutical sector.
Read more →RGENRepligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
Repligen Corporation reported strong financial results for Q3 2025, showcasing an 18% organic growth. The company experienced double-digit revenue growth across all sectors, driven by robust performance in consumables and capital equipment. Due to strong orders and year-to-date performance, Repligen has raised its full-year revenue guidance. The company continues to focus on bioprocessing technology.
Read more →RGENRepligen to Report Third Quarter 2025 Financial Results
Repligen Corporation will announce its third quarter 2025 financial results on October 28, 2025. A press release will precede the market opening, followed by a conference call at 8:30 a.m. ET to discuss the results. The call will be accessible to both domestic and international callers, and a webcast will also be available.
Read more →RGENRepligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
Repligen Corporation has announced a strategic partnership with Novasign to integrate advanced machine learning and modeling workflows into its filtration systems. This collaboration aims to enhance Repligen's digitalization efforts and improve process analytical technology. The partnership is expected to lead to smarter process development, real-time predictive control, and reduced costs and timelines in bioprocessing.
Read more →RGENRepligen Announces Publication of the Company’s 2024 Corporate Sustainability Report
Repligen Corporation has published its 2024 Corporate Sustainability Report, themed 'Perspectives on Progress.' The report outlines the company's advancements in sustainability across six key areas and aligns with the UN Sustainable Development Goals. CEO Olivier Loeillot emphasized the importance of sustainability for business resilience, while VP Dianne Heiler highlighted the commitment to creating business value through sustainable practices.
Read more →RGENRepligen Corporation to Present at William Blair Growth Conference
Repligen Corporation will participate in the William Blair 45th Annual Growth Stock Conference from June 3-5, 2025. CEO Olivier Loeillot is scheduled to present on June 3 at 1:20 p.m. CT. A live webcast of the presentation will be available on the company's Investor Relations website.
Read more →RGENRepligen Corporation to Present at Upcoming May Investor Conferences
Repligen Corporation announced its participation in several investor conferences in May. The company will provide a live webcast of its presentation at the RBC conference, which will also be available for replay. Repligen focuses on innovative bioprocessing technologies that enhance the manufacturing of biological drugs.
Read more →Competitive Position
How RGEN ranks across every disease it competes inCompetitive Position is a premium feature
See how RGEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial